Janssen, Legend’s Carvykti approved in Europe to treat multiple myeloma
The EC conditional marketing authorisation was based on the CARTITUDE-1 study, in which 98% of patients responded to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 May 22
The EC conditional marketing authorisation was based on the CARTITUDE-1 study, in which 98% of patients responded to…
27 May 22
The potential combination therapy comprises diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor ervogastat and an acetyl-CoA carboxylase (ACC) inhibitor clesacostat
26 May 22
Polivy in combination with MabThera (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for adult patients with previously…
25 May 22
The company’s BLA is supported by results from the HOPE-B clinical trial that evaluated the safety and efficacy…
25 May 22
The recall has led to a shortage of baby milk formula products in the US, and the consent…
24 May 22
The EC approval follows positive CHMP recommendation in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19…
23 May 22
The FDA approval is based on data from a Phase 3 trial, conducted in two parts, Part A…
20 May 22
Abevmy marks the third oncology biosimilar to be launched by the partnership in Canada, following Ogivri (bTrastuzumab) in…
20 May 22
The CDSCO approval is based on results from the Phased 3 EMPEROR-Preserved trial which evaluated Jardiance 10mg, compared…
18 May 22
The expanded EUA is based on data, showing booster dose of Pfizer-BioNTech Covid-19 Vaccine induced superior immune response…